Drug
Danegaptide
Danegaptide: highest development phase Phase 2, developed by Zealand Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Zealand Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| danegaptide NCT01977755 | Phase 2 | Focus of Study is STEMI |
Latest
No recent events.
Follow Danegaptide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.